RD
Episodes
3
across 2 shows
First heard
Feb 2026
Guest appearances
2
Episodes per month
Public PodLume episodes featuring it, over the last year.
1
1
1
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 1 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 1 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
Email alert
Email me when Rob Davis comes up on a podcast
One email a week at most, with the new episodes that mention Rob Davis. Free, no account needed, unsubscribe in one click.
What Rob Davis has said on podcasts
8 statements
Merck sees over $70 billion in potential commercial opportunity.
“we now see line of sight to over $70 billion of potential commercial opportunity”
Open the episode · Mad Money w/ Jim Cramer 2/3/26Listen at 33:14
Merck’s ten key growth drivers represent 70% of its potential opportunity.
“Those alone account for 70% of the $70 billion I was referring to.”
Open the episode · Mad Money w/ Jim Cramer 2/3/26Listen at 34:12
Merck’s enlicitide pill could match Repatha efficacy at lower cost.
“we have in the form of a simple to take, easy to use pill that brings like. efficacy that you would get with a drug like Repatha, but at affordable cost”
Open the episode · Mad Money w/ Jim Cramer 2/3/26Listen at 34:46
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
3 episodes featuring Rob Davis, newest first
- Oct 24, 2026
Modern abundance disrupts pleasure and complicates weight lossSomething You Should KnowOct 24, 2026Guest - May 1, 2026
Cramer weighs IPO risks, commodities and Columbia’s next moveMad Money w/ Jim CramerMay 1, 2026 - Feb 4, 2026AI rotation tests software, chips and industrial growthMad Money w/ Jim CramerFeb 4, 2026Guest
Works by Rob Davis
- SL
As an Amazon Associate, PodLume may earn from qualifying purchases.